- Home
- YQ vs RDHL Comparison
YQ vs RDHL Comparison
Compare YQ & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | RDHL |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 3.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | YQ | RDHL |
|---|---|---|
| Price | $4.08 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.7K | ★ 69.2K |
| Earning Date | 12-09-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,563,434.00 | $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $1.26 | $1.01 |
| 52 Week High | $6.45 | $7.00 |
Technical Indicators
Market Signals| Indicator | YQ | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 44.23 |
| Support Level | $3.80 | $1.15 |
| Resistance Level | $4.33 | $1.24 |
| Average True Range (ATR) | 0.47 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 60.41 | 8.79 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.